Author

Eloghosa Aisosa Nosa-Ihaza

Observed names: Eloghosa Aisosaa Nosa-Ihaza, Eloghosa Nosa-Ihaza

Institution: Marwadi University

Observed institution: Marwadi University

ORCID: 0009-0008-8575-1722

Observed ORCIDs: 0009-0008-8575-1722, 0009-0001-8716-0597

OpenAlex ID: A5124156637

Genetic Modification of the BCG Vaccine to Overcome Its Limited Efficacy in Adults: A Specialized Review

2026 · Ssembuusi Allan Francis, Eloghosa Nosa-Ihaza · Research Square · 1

PDF

Antihypertensive Pharmacotherapy Gaps in Nigeria: A Predictive Machine Learning Analysis of Treatment Uptake Amid Macroeconomic Shock, Using NDHS 2023–24

2026 · Eloghosa Aisosa Nosa-Ihaza, Emmanuel Chidera Edeh, et al. · medRxiv

PDF

Antenatal Iron-Folic Acid Supplementation Gaps in Nigeria: A Predictive Machine Learning Analysis of Non-Initiation and Sub-Optimal Duration Using NDHS 2023–24

2026 · Eloghosa Aisosa Nosa-Ihaza, Eze Nnamdi David, et al. · medRxiv

PDF

Predicting Contraceptive Discontinuation in Nigeria: A Machine Learning Analysis of Family-Planning Method Adherence Using NDHS 2023–24 Calendar Data

2026 · Eloghosa Aisosa Nosa-Ihaza, Allan Francis Ssembuusi, et al. · medRxiv

PDF

Antimalarial Pharmacotherapy Gaps in Nigerian Children Under Five: A Predictive Machine Learning Analysis of Care-Seeking, Testing, and ACT Treatment Using NDHS 2023–24

2026 · Eloghosa Aisosa Nosa-Ihaza, Godsent Shepherd-Moses, et al. · medRxiv

PDF

Zero-Dose and Dropout Children in Nigeria: A Comparative Machine Learning Analysis of Childhood Immunization Cascade Failure Using the 2023–24 Nigeria Demographic and Health Survey

2026 · Eloghosa Nosa-Ihaza, Michael Chiebuka Ogidi, et al. · medRxiv

PDF

Artificial Intelligence in Antifungal Drug Discovery Against WHO Critical-Priority Pathogens: Toward a WHO-Aligned, Selectivity-Integrated Discovery Pipeline

2026 · Allan Francis Ssembuusi, Eloghosa Aisosa Nosa-Ihaza · ChemRxiv

PEG Architecture as a Predictor of Anti-PEG Antibody Cross-Reactivity and Sequential Dosing Risk Across PEGylated Nanomedicines

2026 · Ssembuusi Allan Francis, Eloghosa Aisosa Nosa-Ihaza · ChemRxiv

Community-Based Harm Reduction Programs for Opioid Use Disorder: A Narrative Systematic Review of Effectiveness, Implementation Barriers, and Policy Implications

2026 · Eloghosa Aisosaa Nosa-Ihaza, Allan Francis Ssembuusi · ASIDE Internal Medicine

PDF

Ketal versus Ester Linker Hydrolysis in Ionizable Lipids: Mechanistic Implications for Endosomal Escape in mRNA-LNP Therapeutics

2026 · Ssembuusi Allan Francis, Eloghosa Aisosa Nosa-Ihaza · ChemRxiv

Artificial intelligence in cancer immunotherapy: current trends in predicting response and personalizing treatment

2026 · Eloghosa Aisosa Nosa-Ihaza, Emmanuel Chidera Edeh, et al. · Journal of the Egyptian National Cancer Institute

PDF

Addressing the Opioid Crisis Through Community-Based Harm Reduction Programs

2026 · Ssembuusi Allan Francis, Eloghosa Nosa-Ihaza · Research Square

PDF

Next-Generation Splice Therapeutics: Precision Targeting of Alternative Splicing in Genetic Diseases

2026 · Eloghosa Nosa-Ihaza, Godsent Shepherd Moses, et al. · SSRN Electronic Journal

Genomes of Sex: New Genomic and Epigenetic Views on Sex Determination in Bryophytes

2026 · Eloghosa Nosa-Ihaza, Godsent Shepherd-Moses, et al.

Syncmers, Minimizers, and Beyond: Next-Generation Seeding for Scalable Genomics

2026 · Eloghosa Nosa-Ihaza, Okenwa, Ebenezer, et al.

Modern Computational Strategies for Comparative Transcriptomics of Convergent Evolution in Plants

2026 · Eloghosa Nosa-Ihaza, Godsent Shepherd Moses · SSRN Electronic Journal

Genomes of Sex: New Genomic and Epigenetic Views on Sex Determination in Bryophytes

2026 · Eloghosa Nosa-Ihaza, Godsent Shepherd Moses, et al. · SSRN Electronic Journal

Biodegradable Linker Chemistry as a Determinant of Clearance Kinetics and Immunogenicity in Ionizable Lipids for mRNA-LNP Therapeutics: A Structure- Safety Perspective

2026 · Ssembuusi Allan Francis, Eloghosa Nosa-Ihaza

Beyond Payload Immunity: A Vehicle-Directed Immunogenicity Risk Index (VDIRI) for Pre-Treatment Screening Across Gene Therapy Platforms

2026 · Allan Francis Ssembuusi, Eloghosa Nosa-Ihaza · SSRN Electronic Journal

Works count: 19

Citation count: 1

H-index: 1

I10-index: